Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Executives see 2027 improving further and aim for double-digit growth by the end of the decade despite STELARA biosimilar competition. The company plans to detail its long-term growth strategy at an enterprise review in December, highlighting new product launches, a pipeline that includes 12 proof-of-concept molecules in Phase III, and the durability of growth beyond 2030.
Capital spending is focused on Innovative Medicine and MedTech launches, including ICOTYDE, cancer treatments, and the OTTAVA robotic surgical system. J&J also expects continued momentum from its myeloma therapies, ICOTYDE's expanding coverage, and MedTech products, while using acquisitions mainly to support growth beyond the current decade. 5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline programs to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley event, Chief Executive Officer and Chairman Joaquin Duato said the company has become more focused around three Innovative Medicine areas—oncology, immunology and neuroscience—and three MedTech areas: vision, surgery and cardiovascular. → Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Duato said Johnson & Johnson beat analyst expectations for revenue and earnings in the first two quarters of 2026 and raised its outlook. The company's current guidance calls for 6.5% adjusted operational sales growth and 7.3% adjusted earnings-per-share growth in 2026, with total revenue expected to exceed $100 billion for the first time. "We see 2027 being a better year than 2026, and we have line of sight to double-digit growth by the end of the decade," Duato said. → MarketBeat Week in Review – 09/07 - 09/11 5 Stocks the Market Rewarded After Strong Earnings Results Johnson & Johnson plans to hold an enterprise business review in early December, an event it conducts every three years.
Duato said the company intends to provide investors with more detail on the drivers of its goal for double-digit growth by the end of the decade, including its existing portfolio, new product launches and pipeline. The company also plans to discuss the durability of growth beyond 2030, with additional information on earlier-stage pipeline assets. → Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. John Reed, executive vice president of Innovative Medicine and R&D, said the company has 12 molecules that have achieved proof of concept and are in Phase III development.
He added that, beyond DARZALEX, Johnson & Johnson has 10 marketed medicines that are still early in their product life cycles and growing. Duato said Johnson & Johnson's first capital-allocation priority is supporting new product launches in Innovative Medicine and MedTech. He cited the launches of ICOTYDE, an oral IL-23 peptide; INLEXZO for bladder cancer; RYBREVANT in lung cancer; IMAAVY in rheumatological indications; and the OTTAVA soft-tissue robotic surgical system.
The company's second priority is funding its pipeline, including multiple late-stage programs and parallel development across indications, he said. Johnson & Johnson is also seeking earlier-stage business-development opportunities that could benefit from its research, manufacturing and commercial scale. Duato said the company can achieve double-digit growth this decade without acquisitions, but views M&A as a way to reinforce growth into the following decade.
Extract — continue reading at the source.
